We can’t show the full text here under this license.
Using adenine base editing to fix inherited retinal disease mutations in patient stem cells and lab-grown retinal tissue
Updated
Abstract
Essence
Adenine base editing corrected an AIPL1 retinal dystrophy variant in patient-derived iPSCs and retinal organoids, restoring key photoreceptor proteins.
Evidence
A proof-of-principle iPSC and retinal organoid platform experiment tested ABE correction of inherited retinal dystrophy variants, including AIPL1 c.665G>A, p.Trp222*, with modified RNA lipofection and dual-AAV delivery.
Caveat
The evidence is ex vivo and preclinical, with molecular rescue endpoints rather than vision, in vivo safety, or durability outcomes.
Simplified